Amgen's IMDELLTRA Shows 58% Survival Benefit in Phase III SCLC, But Broader Headwinds Persist

What happened

Amgen presented Phase III data at ESMO 2026 showing that adding IMDELLTRA to durvalumab maintenance reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer whose disease had not progressed after initial chemoimmunotherapy. This result strengthens the clinical profile of the DLL3-targeting bispecific, which already holds accelerated approval in this setting, and could support broader use and full approval. However, the DeepValue master report emphasizes that Amgen faces significant structural challenges, including sharp net price declines for ENBREL, a $1.2 billion impairment on Otezla due to IRA price negotiations, and imminent biosimilar erosion for Prolia and XGEVA. While IMDELLTRA adds to the growth-asset mix, it is unlikely to offset the multi-billion dollar profit pool at risk from legacy products and policy-driven pricing pressure. The stock currently trades around $339, near the top of the model's trim range, leaving little valuation buffer for underperformance.

Implication

The survival benefit may enhance IMDELLTRA's commercial trajectory and contribute modestly to revenue growth, but it does not address the larger challenges facing Amgen's portfolio. The IRA-mandated price cuts on ENBREL and Otezla, along with biosimilar competition for Prolia and XGEVA, are expected to significantly reduce cash flows from these blockbusters. Meanwhile, the obesity pipeline, especially MariTide, remains the key value driver and is still unproven in Phase 3. At the current valuation of about 23.7x earnings, the market already prices in successful execution across both newer drugs and the obesity platform. Therefore, investors should remain cautious and wait for a more attractive entry point, ideally below $295, where the risk-reward improves.

Thesis delta

This news does not alter the overall thesis. IMDELLTRA's improved survival data is positive but insufficient to counterbalance the expected erosion in legacy products and policy-driven pricing pressure. The key swing factor remains the obesity platform, particularly MariTide, which has yet to demonstrate phase 3 success.